Real-World Use of Dostarlimab in Endometrial Cancer: A Portuguese Multicenter Study.
INTRODUCTION Dostarlimab has been available in Portugal for advanced or recurrent endometrial cancer post-platinum therapy via an early access program (EAP) since November 2021, with reimbursement from October 2024; its use with carboplatin and paclitaxel was authorized under an early access program in June 2024. The a...